1. E. Fokina,I. Rosly,S. Potekaeva (2014). Laboratory evaluation of erysipelatous imflammation. Epidemiologia i infekcionnye bolezni. Aktualnye voprosy (Epidemiology and infectious diseases. Thrilling questions, 1, 28-32.
2. Martin Denis F,Ploy M.C (2001). Erysipelas: microbiological and pathogenic data. Ann. Dermatol. Venereol, 128, 317-326.
3. S. Morozova,A. Timurzieva (2015). Professional view of the problem of external otitis. iDoctor, 3, 8-11.
4. A. Frolov (2003). Etiopathgenetic particularities of the development of necrotic form of erysipelas, its prediction and principles of complex therapy// Synopsis of PhD thesis. Etiopathgenetic particularities of the development of necrotic form of erysipelas, its prediction and principles of complex therapy// Synopsis of PhD thesis. Irkutsk β
5. M. Mitrofanova,Yu (2010). Disturbances of hemostasis and vascular endothelial function in patients with erysipelas// Synopsis of PhD thesis. Disturbances of hemostasis and vascular endothelial function in patients with erysipelas// Synopsis of PhD thesis. Moscowβ
6. Sheremetiev Yu,G. Makin,F. Suslov,Yu (1995). A method for the registration of the changes of surface erythrocyte charge (lanthanum chloride)// Federal Service for Intellectual Property. Russian Federation Patent β
7. Papachristodoulou D.,Snape A.,Elliott W.H.,Elliott D.C. (2014). Biochemistry and Molecular Biology. Biochemistry and Molecular Biology, 5, 592.
8. E. Fokina (2014). Some particularities of primary erysipelas under present-day conditions.// Terapevtichesky arkhiv (Therapeutic archives) Moscowβ2014. Therapeutic archives, 11, 70-77.
9. F. Castellino,V. Ploplis (2009). The protein C pathway and pathologic processes // J Throm Haemost. Journal of Thrombosis and Haemostasis, 7(1), 140-145.
10. B. Dahlback (1997). Resistance to activated protein C as risk factor for thrombosis: molecular mechanism, laboratory investigation and clinical managements. Semin. Πematol, 34(3), 217-234.
11. Charles Esmon (2001). Role of coagulation inhibitors in inflammation Thromb Haemost. Thrombosis and Haemostasis, 86(07), 51-56.
12. Ratnikova L.I,Dubovikova T.A (2012). Evaluation of the state of vascular platelet hemostasis in patients with hemorrhagic forms of erysipelas// Zhurnal infectologii (Journal of Infectology). Moscowβ, 4(1), 53-57.
13. L. Bockeria,L. Klimovich,A. Potekhina (2004). Mechanisms of coagulation inhibitors involvement into the development of inflammatory reaction and perspective trends of anticoagulation therapy// Klinicheskaya fisiologia krovoobraschenia. Clinical physiology of the circulation, 1, 46-55.
14. Bernard G.R,Vincent J.L (2001). Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med. New England Journal of Medicine, 344(10), 699-709.
15. Shaun Coughlin (2001). Protease-activated receptors in vascular biology Thromb Haemost. Thrombosis and Haemostasis, 86(07), 298-307.
16. Esmon C.T,Taylor F.B (1991). Inflammation and Coagulation: Linked Processes Potentially Regulated Through a Common Pathway Mediated by Protein C. Thrombosis and Haemostasis, 66(01), 160-165.
17. D. Chen,A. Dorling (2009). Dorling A Critical roles for thrombin in acute and chronic inflammation // J Throm Haemost. Journal of Thrombosis and Haemostasis, 7(1), 122-126.
18. Prasanna Sridharan,Ronald Chamberlain (2013). The efficacy of procalcitonin as a biomarker in the management of sepsis: slaying dragons or tilting at windmills? Surg Infect (Larchmt). Surgical Infections, 14(6), 489-511.
19. B. Kile (2009). The role of the intrinsic apoptosis pathway in platelet life and death // J Throm Haemost. Journal of Thrombosis and Haemostasis, 7(1), 214-217.
